Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120. (Q43432407)

23 November 2017

title

Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120. (English)

1 reference

23 November 2017

1 reference

Annemarie N Lekkerkerker

1

1 reference

23 November 2017

Irene S Ludwig

2

1 reference

23 November 2017

Sandra J van Vliet

3

1 reference

23 November 2017

Yvette van Kooyk

4

1 reference

23 November 2017

Teunis B H Geijtenbeek

5

1 reference

23 November 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

23 November 2017

number of pages

12

1 reference

inferred from page(s)

published in

Virology

1 reference

23 November 2017

volume

329

1 reference

23 November 2017

issue

2

1 reference

23 November 2017

page(s)

465-476

1 reference

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Identification of Different Binding Sites in the Dendritic Cell-specific Receptor DC-SIGN for Intercellular Adhesion Molecule 3 and HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Mycobacteria target DC-SIGN to suppress dendritic cell function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Isolation of Lymphocytopathic Retroviruses from San Francisco Patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Macrophage-tropic HIV induces and exploits dendritic cell chemotaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Recruitment of HIV and its receptors to dendritic cell-T cell junctions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Antigenic variation in gp120s from molecular clones of HIV-1 LAI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Inhibition of human immunodeficiency virus type 1 Env-mediated fusion by DC-SIGN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

DC-SIGN and DC-SIGNR: helping hands for HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

DC-SIGN interactions with human immunodeficiency virus: virus binding and transfer are dissociable functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25gag expressed in bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

DC-SIGN: escape mechanism for pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

7 January 2021

Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

7 January 2021

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

7 January 2021

Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

7 January 2021

Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.028

7 January 2021

10.1016/J.VIROL.2004.08.028

Identifiers

DOI

1 reference

23 November 2017

1 reference